Redeye initiates coverage of Acarix

Report this content

Redeye initiates coverage of Acarix. The company's significant potential hinges on its CADScor system’s invention of coronary artery disease (CAD) testing, plus an attractive razor/razorblade model under which high-margin (90%) disposable patches will generate the bulk of sales. While nearer-term upside is limited by the lack of reimbursement, the scope for the CADScor system to become a new standard supports the longer-term case.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.